Screener / SEC EDGAR /CIK 0001649904 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Rhythm Pharmaceuticals, Inc. RYTM

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of RYTM's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Jun 20, 2017
Questions asked 33 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 33 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 0 of 2 closing letter

Form S-1

2017-06-20 to 2017-09-27 · 4 questions · 1 letter from the SEC, 1 from the company
No closing letter
Prospectus Summary · Setmelanotide: A First-in-Class MC4 Agonist, page 2
SEC asked (1)
Please revise to clarify whether the results noted in the last sentence on page 2 were statistically significant.
RYTM answered
On behalf of Rhythm Pharmaceuticals, Inc. (the “Company”), we supplementally submit this letter in response to a verbal comment from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) conveyed by the Staff during a telephone conversation on September 27, 2017 between Jim Rosenberg and Christine Westbrook of the Staff and Laurie Cerveny of this firm. This letter supplements and updates the letters we provided to the Staff on September 18, 2017 (the “Original Letter”) and September 26, 2017 (the “Subsequent Letter”). The Staff’s comment is paraphrased in italics and is followed by the Company’s response.
Rest of the letter

Please provide an explanation for the change from the reverse stock split provided in the Original Letter and the reverse stock split provided in the Supplemental Letter and the impact of that change on the Company’s overall valuation. In the Original Letter, the Company advised the Staff that the Company intended to file with the Commission Amendment No. 1 to the Registration Statement (“Amendment No. 1”) indicating that the Company expected to effect a 1-for-[***] reverse stock split (the “Original Proposed Split”) of all outstanding shares of the Company’s common stock prior to effectiveness of the Registration Statement. In the Subsequent Letter, the Company advised the Staff that it had filed with the Commission on September 25, 2017 Amendment No. 1 indicating that the Company intended to effect a 1-for-9.17 reverse stock split prior to effectiveness of the Registration Statement. In both the Original Letter and the Supplemental Letter, the Company also provided information about its proposed preliminary price range and aggregate valuation of the Company. The Original Proposed Split was determined based on the Company’s fully-diluted capitalization. After submission of the Original Letter, it was determined that the Original Proposed Split had been determined based on an error in the Company’s fully diluted capitalization information which resulted from double counting of certain stock options both as options and outstanding common stock. In order to ensure that the aggregate valuation of the Company was not affected by this error, the anticipated stock split was adjusted, resulting in a higher number of outstanding shares of the Company prior to the IPO. None of the Company’s anticipated IPO price range, the anticipated number of shares to be issued in the IPO or the Company’s Pre-Offering Equity Value or Pre-Offering Equity Value Per Share were impacted by the adjustment to the stock split. Rhythm Pharmaceuticals, Inc. respectfully requests that the information contained in this response be treated as confidential information and that the Commission provide timely notice to Keith Gottesdiener, Chief Executive Officer and President, Rhythm Pharmaceuticals, Inc., 500 Boylston Street, 11th Floor, Boston, MA 02116, (617) 857-4280, before it permits any disclosure of the omitted information in this letter.

One letter for all the questions, without numbered answers. Read the reply
Clinical Development in Rare Genetic Disorders. . . , page 3
SEC asked (2)
Given your disclosure in the Summary and in the Business section on page 107 that your focus is on developing product candidates that will address MC4 upstream indications, it is not appropriate to include the downstream indications and their potential number of patients in the chart on page 3. Please revise so that this prominent graphic is limited to the indications you are focused on addressing.
RYTM answered

See the reply above.

Use of Proceeds, page 70
SEC asked (3)
It appears from your disclosure that the proceeds from the offering will not be sufficient to fund development of setmelanotide through regulatory approval and commercialization for each indication noted in the bullet points in this section. Please disclose the sources of additional funds needed to reach regulatory approval and commercialization of your drug candidates if offering proceeds would not be sufficient.
Rest of the question

Refer to Instruction 3 to Item 504 of Regulation S-K.

RYTM answered

See the reply above.

Clinical Development in Rare Genetic Disorders of Obesity Caused by MC4 Pathway · Deficiencies, page 108
SEC asked (4)
Please remove the statement in the third paragraph of this section that initial clinical trials in patients with general obesity established the safety and efficacy of the drug as these determinations are the province of the U.S. Food and Drug Administration and other comparable regulatory agencies.
RYTM answered

See the reply above.

Form S-1

2015-11-09 to 2017-09-26 · 29 questions · 3 letters from the SEC, 2 from the company
No closing letter
Risk factorsResults discussion (MD&A)Critical estimates
Prospectus Summary · Overview, page 1
SEC asked (1)
Please modify your description of the lack of effective or approved treatments for PWS wherever applicable to note that the FDA has approved the use of human growth hormone for children suffering from this indication.
RYTM answered
On behalf of Rhythm Pharmaceuticals, Inc. (the “Company”), we supplementally submit this letter and the following information in response to a comment from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) initially received in that certain comment letter from the Staff dated November 9, 2015, and verbally reiterated by the Staff in a telephone conversation on August 31, 2017 between Christine Westbrook of the Staff and Laurie Cerveny of this firm.
Rest of the letter

The purpose of this letter is to provide supplemental information to the Staff with respect to the accounting treatment for stock-based compensation for its consideration so that the Company may be in a position to file Amendment No. 1 and print a preliminary prospectus on the anticipated date of September 25, 2017, or as soon thereafter as practicable. We are respectfully requesting confidential treatment for certain portions of this letter pursuant to Rule 83 promulgated by the Commission, 17 C.F.R. Section 200.83. This letter is accompanied by such request for confidential treatment because of the commercially sensitive nature of the +1.617.341.7701 information discussed in this letter. A redacted letter will be filed via Edgar, omitting the confidential information contained in this letter. The Company’s discussion of stock-based compensation is primarily contained within the section of the Company’s Registration Statement on Form S-1 filed on September 5, 2017 (the “S-1”) entitled “Management’s Discussion & Analysis of Financial Condition and Results of Operations — Critical Accounting Policies and Estimates — Stock-Based Compensation (the “MD&A”) and appears on pages 86-93 of the S-1. This section will be revised in Amendment No. 1 to include updated valuation information from August 2017, which is further discussed below. The Staff’s comment is presented in italics and is followed by the Company’s response. We may have additional comments on your accounting for equity issuances including stock compensation and beneficial conversion features. Once you have an estimated offering price, please provide us an analysis explaining the reasons for the differences between recent valuations of your common stock leading up to the IPO and the estimated offering price. Response: In response to the Staff’s comment, the Company provides the following information: The Company supplementally advises the Staff that, while not reflected in the S-1, based on discussions with the Company’s board of directors and reflecting input from the lead underwriters for its initial public offering (“IPO”) the Company currently intends on or about September 25, 2017 to file with the Commission Amendment No. 1 indicating that the Company’s public offering price range is anticipated to be within a $[***] range between $[***] and $[***] (for example, $[***] to $[***]) (giving effect to an anticipated 1-for-[***] reverse stock split of all outstanding shares of the Company’s common stock that the Company plans to implement prior to effectiveness of the Registration Statement) (such price range, the “Preliminary Price Range”). The Estimated Equity Fair Value Per Share amounts used in this letter also reflect the 1-for-[***] reverse stock split. The Company’s final post-split Preliminary Price Range remains under discussion between the Company and the lead underwriters, and a bona fide price range will be included in Amendment No. 1 prior to any distribution of the preliminary prospectus in connection with the Company’s road show. Given the volatility of the public trading markets and the uncertainty of the timing of the offering, the actual price range to be included in a subsequent pre-effective amendment to the Registration Statement may be different from the Preliminary Price Range. [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 Historical Fair Value Determination and Methodology The Company (or, its predecessor, Motus Therapeutics, Inc. (the “Predecessor”) or its prior parent entity, Rhythm Holding Company, LLC (the “LLC entity”)) has performed a contemporaneous valuation of its equity at least once per quarter since May 2015, and in some cases more often than quarterly, in each case with the assistance of an independent third-party valuation specialist (the “Specialist”). The Company’s most recent common stock valuation was as of August 31, 2017. In conducting these valuations, management, the board of directors and the Specialist considered all objective and subjective factors believed to be relevant. The valuations included the best estimate of business conditions, prospects and operating performance at the valuation date. As discussed in the Company’s MD&A, other significant factors considered included: · The lack of an active public market for the Company’s and the LLC entity’s common and preferred equity; · The prices at which the Company and the LLC entity sold preferred equity to outside investors in arm’s length transactions, and the rights, preferences and privileges of that preferred equity, relative to common equity; · The Company’s and the LLC entity’s results of operations, financial position and the status of each entity’s research and clinical development efforts; · The material risks related to the Company’s and the LLC entity’s business; · The market performance of publicly traded companies in the life sciences and biotechnology sectors, and recently completed mergers and acquisitions comparable to the Company and the LLC entity; · The likelihood of achieving a liquidity event for holders of the Company’s and the LLC entity’s common equity, such as an IPO or sale of the Company given prevailing market conditions; and · Any recent contemporaneous valuations of the Company’s and the LLC entity’s common equity prepared in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the “Practice Aid”). Additionally, as described in the S-1, valuations of the Company’s and the LLC entity’s common equity at each valuation date were prepared utilizing the Discounted Cash Flow Method (“DCFM”), the Guideline Public Company Method (“GPCM”), the Option-Pricing Method (“OPM”), the Probability-Weighted Expected Return Method (“PWERM”) or a hybrid of the PWERM and OPM (the “Hybrid Method”). DCFM: Under the DCFM, projected cash flows are converted to present value by applying a discount rate based on an estimated cost of equity or an estimated cost of debt. The cost of equity [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 is estimated based on rates of return required by outside investors. An estimated cost of debt is applied when future cash flows are adjusted for the probability of success in clinical trials. GPCM: Under the GPCM, future value in an IPO is estimated based on a comparison to clinical-stage companies which have completed IPOs. OPM: Under the OPM, common and preferred equity is valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. Under the OPM, common equity only has value if the funds available for distribution to common equity holders exceeds the value of the liquidation preferences at the time of a liquidity event, such as a strategic sale or merger. Under the OPM, the value of one security, such as preferred equity, is used to determine the value of that equity and the corresponding value of the common equity. PWERM: The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to each entity, as well as the economic and control rights of each equity class. Hybrid Method: The Hybrid Method is a PWERM where the equity value in one of the scenarios is calculated using the OPM. The Company employed a Hybrid Method that considered two types of future-event scenarios: an initial public offering and a remain-private scenario.(1) The Company used the OPM to allocate equity value for the unspecified liquidity event. · The enterprise value for the initial public offering scenario was determined using a market approach. Under the market approach, the Company estimated enterprise value using the GPCM. The GPCM includes comparisons to publicly traded companies in the relevant industry that recently completed initial public offerings. Future equity value is converted to present value as of the appraisal date by applying a discount rate derived from studies of the rates of return required by venture capital investors. · For the remain-private scenario, equity value is estimated by using the OPM to backsolve to the adjusted price of the Company’s series A preferred shares. (1) Prior to January 1, 2017, stock-based compensation expense was allocated between the LLC entity and the Company as further discussed in our S-1 at “2. Summary of Significant Accounting Policies — Basis of Presentation”. As allocated LLC entity stock compensation associated with recent valuations was insignificant during the 12 months prior to the date of this letter, the remainder of this letter will be focused on the Company’s recent valuations of its common stock. [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 Beginning with its March 31, 2017 valuation, as the Company anticipated its future and its goals became somewhat more defined by the board to consist of a near-term IPO or sale or an additional private financing, the Company used a modified Hybrid Method that considered two scenarios: a near-term IPO or sale and a remain-private scenario. · The enterprise value for the IPO and sale scenarios was determined using a market approach. Under the market approach, the Company estimated enterprise value using the GPCM. The GPCM includes comparisons to clinical-stage life science companies that recently completed IPOs. Future equity value is converted to present value as of the appraisal date by applying a discount rate derived from studies of the rates of return required by venture capital investors. · For the remain-private scenario, equity value is estimated by using the OPM to backsolve to the adjusted price of the Company’s Series A preferred shares. Discussion of Most Recent Fair Value Determinations Consistent with the discussion above regarding the Company’s modified Hybrid Method, the Company performed a valuation of its common stock as of each of June 30, 2016, September 30, 2016, November 16, 2016, December 31, 2016, March 31, 2017, June 30, 2017 and August 31, 2017 to coincide with the issuance of certain equity compensation grants. The Company valued its equity and allocated equity value using the Hybrid Method. The Hybrid Method considered an IPO and a remain-private scenario in which value is allocated using the OPM. The Company relied on the GPCM to estimate equity value in the IPO scenario. In the remain-private scenario, equity value was determined using an OPM backsolve calculation (a market approach that derives an implied total equity value from the sale price of the Company’s equity securities in a recent arm’s-length transaction). As discussed in the S-1, the March 31, 2017, June 30, 2017 and August 31, 2017 valuations also included a valuation of the Company’s 2017 Series A Investor Instrument, determined to be the sum of the fair values of the 2017 Series A Investor Right/Obligation and 2017 Series A Call Option. The Company valued the 2017 Series A Investor Right/Obligation as the probability-weighted present value of the future benefit associated with the sale of Series A Preferred Stock in August 2017 and valued the 2017 Investor Call Option using the Black-Scholes option model. As of June 30, 2016, the Company’s management and the board of directors assessed the probability of an IPO in February 2017 as [***]% and remain-private scenario in February 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the June 30, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing in October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of June 30, 2016 its estimated fair value per share of its common stock (“Estimated Equity Fair Value Per Share”) was $[***]. As of September 30, 2016, the Company’s management and the board of directors assessed the probability of an IPO in May 2017 as [***]% and remain-private scenario in May 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the September 30, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing in October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of September 30, 2016 its Estimated Equity Fair Value Per Share was $[***]. As of November 16, 2016, the Company’s management and the board of directors assessed the probability of an IPO in May 2017 as [***]% and remain-private scenarios in May 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the November 16, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing in October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The Company also considered the fact that the liquidation preference on its Series A Preferred Stock was continuing to increase as a result of an 8% cumulative dividend, and the fact that the Company’s cash position had decreased approximately $[***] million since the valuation in June 2016. The timing of the future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of November 16, 2016 its Estimated Equity Fair Value Per Share was $[***]. As of December 31, 2016, the Company’s management and the board of directors assessed the probability of an IPO in May 2017 as [***]% and remain-private scenario in May 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the December 31, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing in October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. In addition to the increasing liquidation preference on the Company’s then-outstanding Series A Preferred Stock considered at the November 16, 2016 valuation, the Company also considered the fact that it anticipated issuing in January 2017 an additional $20,475,000 of its Series A Preferred Stock also with an 8% cumulative dividend. The timing of the future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of December 31, 2016 its Estimated Equity Fair Value Per Share was $[***]. As of March 31, 2017, the Company’s management and the board of directors assessed the probability of an IPO in August 2017 as [***]% and remain-private scenario in August 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the March 31, 2017 valuation and the probability weighting of each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of March 31, 2017 its Estimated Equity Fair Value Per Share was $[***]. As of June 30, 2017, the Company’s management and the board of directors assessed the probability of an IPO in October 2017 as [***]% and remain-private scenario in October 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the June 30, 2017 valuation and the probability weighting of each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials in general and, in particular, from the clinical trial studying the use of use of the Company’s product candidate for the treatment of Bardet-Biedl syndrome, (3) prospects for an IPO in the near term, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of June 30, 2017 its Estimated Equity Fair Value Per Share was $[***]. As of August 31, 2017, the Company’s management and the board of directors assessed the probability of an IPO in October 2017 as [***]% and remain-private scenario as [***]%. The Company believes that the potential future liquidity event scenarios used in the August 31, 2017 valuation and the probability weighting of each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials in general and, in particular, from the clinical trial studying the use of use of the Company’s product candidate for the treatment of Bardet-Biedl syndrome, (3) positive feedback received by the Company from investors in the context of “testing-the-waters” meetings conducted by the Company, (4) the addition of a Chief Financial Officer and a Chief Commercial Officer to the Company’s management team, (5) prospects for an IPO in the near term, including the steps taken and to be taken by the Company towards being able to complete an IPO and preparation for a public filing of the Company’s registration statement, (6) general conditions in the capital markets, including with respect to IPOs, and (7) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future event scenarios was determined based primarily on input from the board of directors and management and the Company’s investment bankers. Based on this valuation, the Company has preliminarily determined that as of August 31, 2017 its [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 Estimated Equity Fair Value Per Share was $[***]. As discussed above, the anticipated Preliminary Price Range is expected to be between $[***] and $[***] (giving effect to an anticipated 1-for-[***] reverse stock split). The Preliminary Price Range was derived using a combination of valuation methodologies, including: (a) a comparison of public companies at a similar stage of product development; (b) a comparison of comparable company valuations at the time of their respective IPOs; (c) a comparison of the valuation increases for comparable companies at the time of their respective IPOs; and (d) a discounted cash flow analysis. The following table summarizes the Company’s anticipated pre-offering equity values (based on the low-end, mid-point and high-end of the Preliminary Price Range) (in millions except share data): Comparison of Preliminary Price Range and Estimated Equity Fair Value Per Share The primary factor that accounts for the increase in the Preliminary Price Range over the Company’s determination of Estimated Equity Fair Value Per Share on each of June 30, 2016, September 30, 2016, November 16, 2016, December 31, 2016, June 30, 2017 and August 31, 2017 is the difference in valuation methodology. In particular, because the PWERM utilizes a probability-weighted approach (as discussed above), the resulting Estimated Equity Fair Value Per Share reflects the potential for alternative liquidity events occurring at different future dates, which inherently decreases the Estimated Equity Fair Value Per Share due to the combination of (i) liquidity events other than IPO scenarios; (ii) the discounting to present value for the future business values at each liquidity event; and (iii) the application of a discount for lack of marketability. Conversely, the Preliminary Price Range necessarily assumes only a single outcome, does not apply a discount to present value for the IPO and does not include a discount for lack of marketability, as an active trading market for the Company’s common stock is expected to exist following the IPO. As a result, the Preliminary Price Range was neither reduced by the expected future business values (discounted to present value) from other potential liquidity events nor discounted for a lack of marketability. Additionally, the Preliminary Price Range assumes the [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 conversion of all of the Company’s preferred stock into common stock upon completion of the IPO. The corresponding elimination of the liquidation preferences and rights enjoyed by the holders of the Company’s preferred stock results in a higher valuation for purposes of the Preliminary Price Range, compared to the Estimated Equity Fair Value Per Share, which included the effect of the liquidation preferences for the Company’s preferred stock in relation to the allocations of value in the OPM. While the Company believes the Preliminary Price Range is reasonable, the actual price of the offering, if successful, will be determined by a constantly changing market and actual investor demand. In light of the fact that the increase in the Preliminary Price Range over the Estimated Equity Fair Value Per Share is primarily accounted for by the difference in valuation methodology described above, the Company believes that the deemed per share fair values used as the basis for determining its stock-based compensation expense for financial reporting purposes are reasonable and appropriate. Rhythm Pharmaceuticals, Inc. respectfully requests that the information contained in this response be treated as confidential information and that the Commission provide timely notice to Keith Gottesdiener, Chief Executive Officer and President, Rhythm Pharmaceuticals, Inc., 500 Boylston Street, 11th Floor, Boston, MA 02116, (617) 857-4280, before it permits any disclosure of the omitted information in this letter. We thank you in advance for your consideration of the foregoing. Please contact me at (617) 951-8901 or Keith Gottesdiener, Chief Executive Officer and President at the Company, at (857) 264-4280 with any questions or further comments regarding this letter or the Amendment. [Remainder of page intentionally left blank] [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83

One letter for all the questions, without numbered answers. Read the reply
Prospectus Summary · Overview, page 1
SEC asked (2)
Where you discuss the use of setmelanotide as a treatment for PWS-related obesity and hyperphagia, please briefly explain the impact of being designated an orphan drug. Similarly, please clarify the term “ultra-orphan disease” used in reference to POMC deficiency.
RYTM answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (3)
Please note in this summary and the risk factor concerning product development on page 16 that the Phase 2 clinical trial in POMC deficiency has only enrolled one patient to date.
RYTM answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (4)
Where you reference the previous clinical trials that enrolled over 200 patients, please note here and in the risk factor on page 16 that those trials did not demonstrate statistically significant results when setmelanotide was administered using continuous infusion, and that this led you to rely upon daily subcutaneous infection as the sole delivery method.
RYTM answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (5)
In your discussion of the use of setmelanotide for the treatment of obesity and hyperphagia in POMC deficiency and certain other indications, you state that you intend to pursue an accelerated path to approval. Please elaborate on the “accelerated path” you are referring to, including whether you intend to seek orphan drug or breakthrough therapy designations for this indication.
RYTM answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (6)
Please revise your disclosure in the Summary, and particularly when you first introduce a scientific concept or a disease target, to provide an explanation of the scientific concept that is accessible for a reader who may lack scientific training.
Rest of the question

For instance, on page 1 you discuss how MC4 deficiency may be a contributing factor in obese patients, particularly patients suffering from PWC or POMC who have MC4 deficiencies. Please revise this section to explain how MC4 deficiency may cause a patient to become obese, for instance because the body does not receive normal satiety signals. Similarly, please explain how setmelanotide works to remediate the MC4 deficiency.

RYTM answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (7)
At first use, please define the following terms or concepts:  “energy homeostatis;”  “upstream” defects or deficiencies;
RYTM answered

See the reply above.

 “LepR deficiency.” · Corporate Restructuring, page 12
SEC asked (8)
Please indicate here, and wherever applicable in your Business section, which entity filed an Investigational New Drug Application for setmelanotide and approximately when that filing was made with the FDA. Please also indicate which entity has conducted or is conducting, as applicable, the clinical trials performed to date on setmelanotide.
Rest of the question

Risk Factors Risks Related to the Development of Our Product Candidates “The number of patients suffering from each of the MC4 pathway deficiencies we are targeting is small . . .,” page 17

RYTM answered

See the reply above.

 “LepR deficiency.” · Corporate Restructuring, page 12
SEC asked (9)
Please remove the cross-reference to this risk factor at the end of this page, as it appears to be there in error. “Changes in regulatory requirements, FDA guidance or unanticipated events during our clinical trial of setmelanotide may occur . . .,” page 20
RYTM answered

See the reply above.

 “LepR deficiency.” · Corporate Restructuring, page 12
SEC asked (10)
Please amend this risk factor to briefly explain what the PRO and ORO questionnaires are. Please make similar changes to your disclosure regarding the regulatory review process.
RYTM answered

See the reply above.

“Our product candidates may cause additional side effects . . .,” page 21
SEC asked (11)
Here, and in your disclosure on page 93, please identify the clinical trial that resulted in the serious adverse event and quantify, and briefly describe, the adverse events you have identified in your clinical testing to date. Risks Related to Employee Matters and Managing Growth “Following consummation of this offering, our executive officers intend to provide consulting services to the Relamorelin Company . .
Rest of the question

.,” page 44

RYTM answered

See the reply above.

“Our product candidates may cause additional side effects . . .,” page 21
SEC asked (12)
Please indicate, to the best of your knowledge, how much time, if any, these executive officers currently devote to the Relamorelin Company and approximately how much time they will be contractually obligated to spend on their consulting services once the agreements are in place. Please make similar changes to your disclosure on page 117.
RYTM answered

See the reply above.

“The indirect ownership of our executive officers…, page 44
SEC asked (13)
Please revise this section to identify all directors who will continue to have an ownership interest in Relamorelin (or its successor Motus Therapeutics) after the offering.
RYTM answered

See the reply above.

Use of Proceeds, page 55
SEC asked (14)
Please amend this disclosure to separate the amount of offering proceeds you intend to allocate toward development of setmelanotide as a treatment for Prader Willi Syndrome from the amount intended for its development as a treatment for POMC deficiency obesity.
RYTM answered

See the reply above.

Critical Accounting Policies and Estimates · Stock-based compensation, page 67
SEC asked (15)
We may have additional comments on your accounting for equity issuances including stock compensation and beneficial conversion features. Once you have an estimated offering price, please provide us an analysis explaining the reasons for the differences between recent valuations of your common stock leading up to the IPO and the estimated offering price.
RYTM answered

See the reply above.

Business · General
SEC asked (16)
We note your discussion in the risk factor on page 17, and again in the Market and Other Data section on page 42 regarding the limited information on the number of patients who may be impacted by PWS and POMC. Please revise your disclosure in this section to discuss in greater detail the difficulty in identifying the number of possible patients, your efforts to provide more specificity and management’s view of
Rest of the question

whether those efforts are statistically valid in estimating the number of patients who might be impacted by the diseases that your therapies are targeting.

RYTM answered

See the reply above.

Overview, page 75
SEC asked (17)
Please describe the consultations with the FDA you reference on page 76, including the approximate dates of any meetings and the guidance, if any, you received in each one.
RYTM answered

See the reply above.

Market Overview, page 78
SEC asked (18)
Please explain on page 78 what a “hypothalamic pathway” is.
RYTM answered

See the reply above.

Setmelanotide: A First-in-Class Phase 2 MCAR Agonist, page 83
SEC asked (19)
In the table on page 84, please change the clinical trial phase for POMC heterozygous deficiency and LepR deficiency from Phase 2 to Phase 1. Your disclosure should reflect the actual, and not the anticipated, clinical status of your product candidate for all its indications.
RYTM answered

See the reply above.

Setmelanotide: A First-in-Class Phase 2 MCAR Agonist, page 83
SEC asked (20)
Where you discuss the Phase 2 clinical trials currently underway, please indicate the pvalues for each that you are using to measure statistical significance, and the p-value determined for the one subject who has been tested for POMC deficiency.
RYTM answered

See the reply above.

Setmelanotide: A First-in-Class Phase 2 MCAR Agonist, page 83
SEC asked (21)
In your discussion of the Phase 2 clinical trial for PWS on page 87, please indicate what the secondary endpoints of this trial are, if any.
RYTM answered

See the reply above.

Setmelanotide: A First-in-Class Phase 2 MCAR Agonist, page 83
SEC asked (22)
Please indicate approximately when the Phase 1 clinical trials for setmelanotide as a treatment in connection with POMC heterozygous and LepR deficiency were performed and describe their results.
RYTM answered

See the reply above.

Safety and Tolerability, page 92
SEC asked (23)
Please revise this section to clarify the differences between your current MC4 agonist (setmelanotide) and the first generation agonist that produced safety issues. Please also clarify the total number of patients involved in your Phase1b and ongoing Phase 2 trials compared to the number involved in the first generation testing.
RYTM answered

See the reply above.

Other Comments
SEC asked (24)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
RYTM answered

See the reply above.

SEC letter of Dec 23, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary · Overview, page 1
SEC asked (1)
We note your response to prior comment 3. In each page you reference in your response, please amend your disclosure to explicitly state that only two patients are currently enrolled and receiving treatment in the clinical trial.
RYTM answered

No reply letter found.

Business · General
SEC asked (2)
We note your response to prior comment 16, in which you discuss your efforts to statistically model the possible patient population. As requested, please discuss whether management believes that the estimates are statistically valid. Also, please expand this section to discuss any further efforts you have undertaken to assess the potential number of patients that might be impacted by MC4 pathway deficiency.
RYTM answered

No reply letter found.

Overview, page 79
SEC asked (3)
We note your response to prior comment 17. Please amend your disclosure to include the information you have supplementally provided in your response, as it directly addresses our comment.
RYTM answered

No reply letter found.

Notes to Financial Statements · Preferred Stock, page F-15
SEC asked (4)
Please tell us why you believe the classification of your Series A Convertible Preferred Stock within Stockholder’s Equity is appropriate. Refer to ASC 480-10-S99-3A.3.f.
RYTM answered

No reply letter found.

Business · Licensing Agreements, page 103
SEC asked
In your description of the license agreement you entered into with Camurus AB, please include the duration and termination provisions of the agreement, as well as the amount of the upfront payment you made.
RYTM answered
On behalf of Rhythm Pharmaceuticals, Inc. (the “Company”), we supplementally submit this letter and the following information in response to a comment from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) initially received in that certain comment letter from the Staff dated November 9, 2015, and verbally reiterated by the Staff in a telephone conversation on August 31, 2017 between Christine Westbrook of the Staff and Laurie Cerveny of this firm. This letter supplements and updates the letter we provided to the Staff on September 18, 2017 (the “Original Letter”).
Rest of the letter

With the exception of a change in the stock split from a 1-for-[***] reverse stock split to a 1-for-9.17 reverse stock split, and any resulting impact on share numbers and prices resulting from that change, the remainder of the information set forth herein and in the supplemental data provided herewith have not changed from that provided previously. We have supplementally provided a redline of this letter to the Original Letter for the Staff’s convenience The purpose of this letter is to provide supplemental information to the Staff with respect +1.617.341.7701 to the accounting treatment for stock-based compensation as provided by the Company in its Form S-1 filed on September 5, 2017 (the “S-1”), as amended by Amendment No. 1 and the preliminary prospectus contained therein. We are respectfully requesting confidential treatment for certain portions of this letter and for the accompanying supplemental information pursuant to Rule 83 promulgated by the Commission, 17 C.F.R. Section 200.83. This letter is accompanied by such request for confidential treatment because of the commercially sensitive nature of the information discussed in this letter. A redacted letter will be filed via Edgar, omitting the confidential information contained in this letter. The Company’s discussion of stock-based compensation is primarily contained within the section of Amendment No. 1 entitled “Management’s Discussion & Analysis of Financial Condition and Results of Operations — Critical Accounting Policies and Estimates — Stock-Based Compensation (the “MD&A”) and appears on pages 86-93 of Amendment No. 1. The Staff’s comment is presented in italics and is followed by the Company’s response. We may have additional comments on your accounting for equity issuances including stock compensation and beneficial conversion features. Once you have an estimated offering price, please provide us an analysis explaining the reasons for the differences between recent valuations of your common stock leading up to the IPO and the estimated offering price. Response: In response to the Staff’s comment, the Company provides the following information: As was reflected in the Original Letter, the Company supplementally advises the Staff that, while not reflected in the S-1, based on discussions with the Company’s board of directors and reflecting input from the lead underwriters for its initial public offering (“IPO”) at the time of the Original Letter, the Company intended on or about September 25, 2017 to file with the Commission Amendment No. 1 indicating that the Company’s public offering price range is anticipated to be within a $[***] range between $[***] and $[***] (for example, $[***] to $[***]) (giving effect to an anticipated 1-for-[***] reverse stock split of all outstanding shares of the Company’s common stock that the Company plans to implement prior to effectiveness of the Registration Statement) (such price range, the “Preliminary Price Range”). As is reflected in the Amendment No. 1, based on further discussions with the board of directors and reflecting input from the lead underwriters in its IPO, Amendment No. 1 reflects a price range of $14,00 to $16.00 (the “Price Range”) and a 1-for-9.17 reverse stock split. The Estimated Equity Fair Value Per Share amounts used in this letter also reflect the 1-for-9.17 reverse stock split. [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 The Company’s final post-split Price Range remains under discussion between the Company and the lead underwriters and will be based on the market for the Company’s stock as determined based on the road show currently underway. Given the volatility of the public trading markets and the uncertainty of the timing of the offering, the actual price range to be included in a subsequent pre-effective amendment to the Registration Statement may be different from the Preliminary Price Range. Historical Fair Value Determination and Methodology The Company (or, its predecessor, Motus Therapeutics, Inc. (the “Predecessor”) or its prior parent entity, Rhythm Holding Company, LLC (the “LLC entity”)) has performed a contemporaneous valuation of its equity at least once per quarter since May 2015, and in some cases more often than quarterly, in each case with the assistance of an independent third-party valuation specialist (the “Specialist”). The Company’s most recent common stock valuation was as of August 31, 2017. In conducting these valuations, management, the board of directors and the Specialist considered all objective and subjective factors believed to be relevant. The valuations included the best estimate of business conditions, prospects and operating performance at the valuation date. As discussed in the Company’s MD&A, other significant factors considered included: · The lack of an active public market for the Company’s and the LLC entity’s common and preferred equity; · The prices at which the Company and the LLC entity sold preferred equity to outside investors in arm’s length transactions, and the rights, preferences and privileges of that preferred equity, relative to common equity; · The Company’s and the LLC entity’s results of operations, financial position and the status of each entity’s research and clinical development efforts; · The material risks related to the Company’s and the LLC entity’s business; · The market performance of publicly traded companies in the life sciences and biotechnology sectors, and recently completed mergers and acquisitions comparable to the Company and the LLC entity; · The likelihood of achieving a liquidity event for holders of the Company’s and the LLC entity’s common equity, such as an IPO or sale of the Company given prevailing market conditions; and · Any recent contemporaneous valuations of the Company’s and the LLC entity’s common equity prepared in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the “Practice Aid”). [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 Additionally, as described in Amendment No. 1, valuations of the Company’s and the LLC entity’s common equity at each valuation date were prepared utilizing the Discounted Cash Flow Method (“DCFM”), the Guideline Public Company Method (“GPCM”), the Option-Pricing Method (“OPM”), the Probability-Weighted Expected Return Method (“PWERM”) or a hybrid of the PWERM and OPM (the “Hybrid Method”). DCFM: Under the DCFM, projected cash flows are converted to present value by applying a discount rate based on an estimated cost of equity or an estimated cost of debt. The cost of equity is estimated based on rates of return required by outside investors. An estimated cost of debt is applied when future cash flows are adjusted for the probability of success in clinical trials. GPCM: Under the GPCM, future value in an IPO is estimated based on a comparison to clinical-stage companies which have completed IPOs. OPM: Under the OPM, common and preferred equity is valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. Under the OPM, common equity only has value if the funds available for distribution to common equity holders exceeds the value of the liquidation preferences at the time of a liquidity event, such as a strategic sale or merger. Under the OPM, the value of one security, such as preferred equity, is used to determine the value of that equity and the corresponding value of the common equity. PWERM: The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to each entity, as well as the economic and control rights of each equity class. Hybrid Method: The Hybrid Method is a PWERM where the equity value in one of the scenarios is calculated using the OPM. The Company employed a Hybrid Method that considered two types of future-event scenarios: an initial public offering and a remain-private scenario.(1) The Company used the OPM to allocate equity value for the unspecified liquidity event. (1) Prior to January 1, 2017, stock-based compensation expense was allocated between the LLC entity and the Company as further discussed in Amendment No. 1 at “2. Summary of Significant Accounting Policies — Basis of Presentation”. As allocated LLC entity stock compensation associated with recent valuations was insignificant during the 12 months prior to the date of this letter, the remainder of this letter will be focused on the Company’s recent valuations of its common stock. [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 · The enterprise value for the initial public offering was determined using a market approach. Under the market approach, the Company estimated enterprise value using the GPCM. The GPCM includes comparisons to publicly traded companies in the relevant industry that recently completed initial public offerings. Future equity value is converted to present value as of the appraisal date by applying a discount rate derived from studies of the rates of return required by venture capital investors. · For the remain-private scenario, equity value is estimated by using the OPM to backsolve to the adjusted price of the Company’s series A preferred shares. Beginning with its March 31, 2017 valuation, as the Company anticipated its future and its goals became somewhat more defined by the board to consist of a near-term IPO or sale or an additional private financing, the Company used a modified Hybrid Method that considered two scenarios: a near-term IPO or sale and a remain-private scenario. · The enterprise value for the IPO and sale scenarios was determined using a market approach. Under the market approach, the Company estimated enterprise value using the GPCM. The GPCM includes comparisons to clinical-stage life science companies that recently completed IPOs. Future equity value is converted to present value as of the appraisal date by applying a discount rate derived from studies of the rates of return required by venture capital investors. · For the remain-private scenario, equity value is estimated by using the OPM to backsolve to the adjusted price of the Company’s Series A preferred shares. Discussion of Most Recent Fair Value Determinations Consistent with the discussion above regarding the Company’s modified Hybrid Method, the Company performed a valuation of its common stock as of each of June 30, 2016, September 30, 2016, November 16, 2016, December 31, 2016, March 31, 2017, June 30, 2017 and August 31, 2017 to coincide with the issuance of certain equity compensation grants. The Company valued its equity and allocated equity value using the Hybrid Method. The Hybrid Method considered an IPO and a remain-private scenario in which value is allocated using the OPM. The Company relied on the GPCM to estimate equity value in the IPO scenario. In the remain-private scenario, equity value was determined using an OPM backsolve calculation (a market approach that derives an implied total equity value from the sale price of the Company’s equity securities in a recent arm’s-length transaction). As discussed in Amendment No. 1, the March 31, 2017, June 30, 2017 and August 31, 2017 valuations also included a valuation of the Company’s 2017 Series A Investor Instrument, determined to be the sum of the fair values of the 2017 Series A Investor Right/Obligation and 2017 Series A Call Option. The Company valued the 2017 Series A Investor Right/Obligation as the probability-weighted present value of the future benefit [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 associated with the sale of Series A Preferred Stock in August 2017 and valued the 2017 Investor Call Option using the Black-Scholes option model. As of June 30, 2016, the Company’s management and the board of directors assessed the probability of an IPO in February 2017 as [***]% and remain-private scenario in February 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the June 30, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing on October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of June 30, 2016 its estimated fair value per share of its common stock (“Estimated Equity Fair Value Per Share”) was $[***]. As of September 30, 2016, the Company’s management and the board of directors assessed the probability of an IPO in May 2017 as [***]% and remain-private scenario in May 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the September 30, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing on October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of September 30, 2016 its Estimated Equity Fair Value Per Share was $[***]. As of November 16, 2016, the Company’s management and the board of directors assessed the probability of an IPO in May 2017 as [***]% and remain-private scenarios in May 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the November 16, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing on October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 light of prevailing market conditions. The Company also considered the fact that the liquidation preference on its Series A Preferred Stock was continuing to increase as a result of an 8% cumulative dividend, and the fact that the Company’s cash position had decreased approximately $[***] million since the valuation in June 2016. The timing of the future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of November 16, 2016 its Estimated Equity Fair Value Per Share was $[***]. As of December 31, 2016, the Company’s management and the board of directors assessed the probability of an IPO in May 2017 as [***]% and remain-private scenario in May 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the December 31, 2016 valuation and the probability of weighting each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing on October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. In addition to the increasing liquidation preference on the Company’s then-outstanding Series A Preferred Stock considered at the November 16, 2016 valuation, the Company also considered the fact that it anticipated issuing in January 2017 an additional $20,475,000 of its Series A Preferred Stock also with an 8% cumulative dividend. The timing of the future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of December 31, 2016 its Estimated Equity Fair Value Per Share was $[***]. As of March 31, 2017, the Company’s management and the board of directors assessed the probability of an IPO in August 2017 as [***] and remain-private scenario in August 2017 as [***]. The Company believes that the potential future liquidity event scenarios used in the March 31, 2017 valuation and the probability weighting of each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials, (3) prospects for an IPO in the near term, including the amount of time that had passed since the Company’s first confidential filing on October 2015, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of March 31, 2017 its Estimated Equity Fair Value Per Share was $[***]. [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 As of June 30, 2017, the Company’s management and the board of directors assessed the probability of an IPO in October 2017 as [***]% and remain-private scenario in October 2017 as [***]%. The Company believes that the potential future liquidity event scenarios used in the June 30, 2017 valuation and the probability weighting of each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials in general and, in particular, from the clinical trial studying the use of use of the Company’s product candidate for the treatment of Bardet-Biedl syndrome, (3) prospects for an IPO in the near term, (4) general conditions in the capital markets, including with respect to IPOs, and (5) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future liquidity event scenarios was determined based primarily on input from the board of directors and management. Based on this valuation, the Company determined that as of June 30, 2017 its Estimated Equity Fair Value Per Share was $[***]. As of August 31, 2017, the Company’s management and the board of directors assessed the probability of an IPO in October 2017 as [***]% and remain-private scenario as [***]%. The Company believes that the potential future liquidity event scenarios used in the August 31, 2017 valuation and the probability weighting of each future event were appropriate at the time in light of (1) the Company’s state of development and operating results, (2) the most recent data generated by the Company from its clinical trials in general and, in particular, from the clinical trial studying the use of use of the Company’s product candidate for the treatment of Bardet-Biedl syndrome, (3) positive feedback received by the Company from investors in the context of “testing-the-waters” meetings conducted by the Company, (4) the addition of a Chief Financial Officer and a Chief Commercial Officer to the Company’s management team, (5) prospects for an IPO in the near term, including the steps taken and to be taken by the Company towards being able to complete an IPO and preparation for a public filing of the Company’s registration statement, (6) general conditions in the capital markets, including with respect to IPOs, and (7) the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. The timing of these future event scenarios was determined based primarily on input from the board of directors and management and the Company’s investment bankers. Based on this valuation, the Company has preliminarily determined that as of August 31, 2017 its Estimated Equity Fair Value Per Share was $[***]. As discussed above, the anticipated Preliminary Price Range in the Original Letter was expected to be between $[***] and $[***] (giving effect to an anticipated 1-for-[***] reverse stock split) and the Price Range in Amendment No. 1 is $14.00 to $16.00 (given effect to a 1-for-9.17 reverse stock split). The remainder of this discussion reflects the 1-for-9.17 reverse stock split. [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 The Preliminary Price Range was derived using a combination of valuation methodologies, including: (a) a comparison of public companies at a similar stage of product development; (b) a comparison of comparable company valuations at the time of their respective IPOs; (c) a comparison of the valuation increases for comparable companies at the time of their respective IPOs; and (d) a discounted cash flow analysis. The following table summarizes the Company’s anticipated pre-offering equity values (based on the low-end, mid-point and high-end of the Preliminary Price Range) (in millions except share data): Comparison of Preliminary Price Range and Estimated Equity Fair Value Per Share The primary factor that accounts for the increase in the Preliminary Price Range over the Company’s determination of Estimated Equity Fair Value Per Share on each of June 30, 2016, September 30, 2016, November 16, 2016, December 31, 2016, March 31, 2017, June 30, 2017 and August 31, 2017 is the difference in valuation methodology. In particular, because the PWERM utilizes a probability-weighted approach (as discussed above), the resulting Estimated Equity Fair Value Per Share reflects the potential for alternative liquidity events occurring at different future dates, which inherently decreases the Estimated Equity Fair Value Per Share due to the combination of (i) liquidity events other than IPO scenarios; (ii) the discounting to present value for the future business values at each liquidity event; and (iii) the application of a discount for lack of marketability. Conversely, the Preliminary Price Range necessarily assumes only a single outcome, does not apply a discount to present value for the IPO and does not include a discount for lack of marketability, as an active trading market for the Company’s common stock is expected to exist following the IPO. As a result, the Preliminary Price Range was neither reduced by the expected future business values (discounted to present value) from other potential liquidity events nor discounted for a lack of marketability. Additionally, the Preliminary Price Range assumes the conversion of all of the Company’s preferred stock into common stock upon completion of the IPO. The corresponding elimination of the liquidation preferences and rights enjoyed by the holders of the Company’s preferred stock results in a higher valuation for purposes of the Preliminary Price Range, compared to the Estimated Equity Fair Value Per Share, which included the effect of the liquidation preferences for the Company’s preferred stock in relation to the allocations of value in the OPM. [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83 While the Company believes the Preliminary Price Range is reasonable, the actual price of the offering, if successful, will be determined by a constantly changing market and actual investor demand. In light of the fact that the increase in the Preliminary Price Range over the Estimated Equity Fair Value Per Share is primarily accounted for by the difference in valuation methodology described above, the Company believes that the deemed per share fair values used as the basis for determining its stock-based compensation expense for financial reporting purposes are reasonable and appropriate. Rhythm Pharmaceuticals, Inc. respectfully requests that the information contained in this response and in the supplemental material provided herewith be treated as confidential information and that the Commission provide timely notice to Keith Gottesdiener, Chief Executive Officer and President, Rhythm Pharmaceuticals, Inc., 500 Boylston Street, 11th Floor, Boston, MA 02116, (617) 857-4280, before it permits any disclosure of the omitted information in this letter. We thank you in advance for your consideration of the foregoing. Please contact me at (617) 951-8901 or Keith Gottesdiener, Chief Executive Officer and President at the Company, at (857) 264-4280 with any questions or further comments regarding this letter or the Amendment. [Remainder of page intentionally left blank] [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED BY RHYTHM PHARMACEUTICALS UNDER 17 C.F.R. Section 200.83

One letter for all the questions, without numbered answers. Read the reply

Letters without questions

Other letters

UPLOAD and CORRESP
7 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 14 letters filed since 2015-11-10. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RYTM/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.